Rimonabant-Induced Persistent Vomiting

Samir Kumar Praharaj; Sujit Sarkhel

Rimonabant-Induced Persistent Vomiting

Samir Kumar Praharaj
, Sujit Sarkhel

Research output: Contribution to journal › Article › peer-review

Abstract

Rimonabant is a selective cannabinoid-1 receptor blocker, which may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese. Rimonabant is generally well tolerated but the most common drugrelated adverse event reported in trials is nausea. We report a case of persistent vomiting associated with rimonabant therapy for reduction of body weight gain in a patient with paranoid schizophrenia, which resolved following discontinuation of medication and symptomatic treatment.

Original language	English
Pages (from-to)	49-50
Number of pages	2
Journal	German Journal of Psychiatry
Volume	16
Issue number	1
Publication status	Published - 24-07-2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Psychiatry and Mental health

Cite this

@article{35df95868e374ef696dd2a8740dc214c,

title = "Rimonabant-Induced Persistent Vomiting",

abstract = "Rimonabant is a selective cannabinoid-1 receptor blocker, which may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese. Rimonabant is generally well tolerated but the most common drugrelated adverse event reported in trials is nausea. We report a case of persistent vomiting associated with rimonabant therapy for reduction of body weight gain in a patient with paranoid schizophrenia, which resolved following discontinuation of medication and symptomatic treatment.",

author = "Praharaj, \{Samir Kumar\} and Sujit Sarkhel",

year = "2013",

month = jul,

day = "24",

language = "English",

volume = "16",

pages = "49--50",

journal = "German Journal of Psychiatry",

issn = "1433-1055",

publisher = "University of Goettingen",

number = "1",

}

TY - JOUR

T1 - Rimonabant-Induced Persistent Vomiting

AU - Praharaj, Samir Kumar

AU - Sarkhel, Sujit

PY - 2013/7/24

Y1 - 2013/7/24

N2 - Rimonabant is a selective cannabinoid-1 receptor blocker, which may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese. Rimonabant is generally well tolerated but the most common drugrelated adverse event reported in trials is nausea. We report a case of persistent vomiting associated with rimonabant therapy for reduction of body weight gain in a patient with paranoid schizophrenia, which resolved following discontinuation of medication and symptomatic treatment.

AB - Rimonabant is a selective cannabinoid-1 receptor blocker, which may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese. Rimonabant is generally well tolerated but the most common drugrelated adverse event reported in trials is nausea. We report a case of persistent vomiting associated with rimonabant therapy for reduction of body weight gain in a patient with paranoid schizophrenia, which resolved following discontinuation of medication and symptomatic treatment.

UR - https://www.scopus.com/pages/publications/84880814317

UR - https://www.scopus.com/pages/publications/84880814317#tab=citedBy

M3 - Article

AN - SCOPUS:84880814317

SN - 1433-1055

VL - 16

SP - 49

EP - 50

JO - German Journal of Psychiatry

JF - German Journal of Psychiatry

IS - 1

ER -

Rimonabant-Induced Persistent Vomiting

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Other files and links

Fingerprint

Cite this